Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Melphalan
Drug ID BADD_D01376
Description An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - melphalan, the racemic mixture - merphalan, and the dextro isomer - medphalan; toxic to bone marrow, but little vesicant action; potential carcinogen.
Indications and Usage For the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. Has also been used alone or as part of various chemotherapeutic regimens as an adjunct to surgery in the treatment of breast cancer, alone or in combination regimens for palliative treatment of locally recurrent or unresectable in-transit metastatic melanoma of the extremities, as well as for the treatment of amyloidosis with prednisone.
Marketing Status Prescription; Discontinued
ATC Code L01AA03
DrugBank ID DB01042
KEGG ID D00369
MeSH ID D008558
PubChem ID 460612
TTD Drug ID D00FGO
NDC Product Code 68152-109; 71052-158; 52609-0001; 68554-0076; 50683-0385; 72893-001; 43744-361; 76055-0021; 72969-046
Synonyms Melphalan | L-PAM | Phenylalanine Mustard | Mustard, Phenylalanine | 4-(Bis(2-chloroethyl)amino)phenylalanine | Medphalan | Sarkolysin | Sarcolysine | Merphalan | Alkeran
Chemical Information
Molecular Formula C13H18Cl2N2O2
CAS Registry Number 148-82-3
SMILES C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Chromosomal abnormalities and abnormal gene carriersTribbles homolog 3Q96RU7Not Available11359799; 12649745; 10843675
InjuryElongator complex protein 1O95163T4988811359799; 12649745; 10843675
InjuryT-lymphocyte activation antigen CD80P33681T5823811359799; 12649745; 10843675
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Optic atrophy06.09.02.0010.000799%Not Available
Osteoporosis15.02.03.002; 14.04.04.0020.000533%
Ovarian failure21.11.02.005; 05.05.01.0120.000533%Not Available
Pain08.01.08.004--
Pancreatitis acute07.18.01.0020.000533%Not Available
Pancytopenia01.03.03.0030.001066%Not Available
Paraesthesia17.02.06.005--
Plasma cell myeloma16.23.02.004; 01.14.02.0040.000139%Not Available
Plasmacytoma16.23.02.002; 01.14.02.002--Not Available
Platelet count decreased13.01.04.0010.000533%
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Prothrombin level increased13.01.02.0110.008792%Not Available
Pruritus23.03.12.001--
Pulmonary fibrosis22.01.02.006--
Pyrexia08.05.02.0030.001066%
Radiation myelopathy17.10.01.014; 12.05.02.007--Not Available
Rales22.02.04.004--Not Available
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.004--
Respiratory distress22.02.01.012--Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000347%
Retinal detachment06.09.03.003; 12.01.04.0040.001598%
Retinal haemorrhage24.07.05.003; 06.10.01.0010.001332%Not Available
Retinal ischaemia24.04.10.005; 06.10.01.0090.000533%Not Available
Retinal vasculitis10.02.02.021; 06.04.06.0110.002131%Not Available
Retinopathy24.03.07.003; 06.10.02.0010.002131%
Rhabdomyolysis15.05.05.002--
Seizure17.12.03.001--
Sepsis11.01.11.0030.000278%
Septic shock24.06.02.011; 11.01.11.0040.000139%Not Available
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages